Introduction {#Sec1}
============

Gaucher disease (GD), one of the most prevalent lysosomal storage disorder, results from defective β-glucocerebrosidase production and subsequent accumulation of glucocerebroside in macrophages (Zimran and Elstein [@CR22]). Enzyme replacement therapy (ERT) became available in 1991 (Barton et al [@CR1]) leading to improvement in hemoglobin levels and platelet counts, and to reduction of splenic and hepatic enlargement (Weinreb et al [@CR17]; Zimran and Elstein [@CR21]), but the bone response lagged behind the visceral and hematological improvements (Lebel et al [@CR6]; Wenstrup et al [@CR18]).

Infiltration of the bone marrow by Gaucher cells reduces the bone marrow fat fraction (FF), and the reduction in lumbar spine FF is closely related to the extent of skeletal manifestations of GD (Rosenthal et al [@CR11]; Maas et al [@CR8]). The Dixon-quantitative chemical shift imaging (QCSI) was developed in The Academic Medical Center (AMC), Amsterdam, as a technique that measures displacement of fatty marrow by Gaucher cells using the mean value of the FF in vertebrae L3, L4, and L5 (Hollak et al [@CR5]; van Dussen et al [@CR15]). The FF measured in patients with GD ranged from 0.08 to 0.40 (mean 0.20), significantly lower than in the healthy population (range 0.27 to 0.55; mean 0.37; *p* \< 0.001), while bone complications occurred primarily in patients with a FF of less than 0.23, indicative of "bone at risk" (Maas et al [@CR8]).

Taliglucerase alfa is the first plant cell--expressed recombinant therapeutic protein approved for use in humans and is approved for the treatment of patients with GD in multiple countries (Zimran et al [@CR19]; Grabowski et al [@CR4]; Tekoah et al [@CR14]). In 2012, we reported improvement in QCSI in a sub-group of eight patients from the pivotal taliglucerase alfa clinical trial, who were willing to travel to the AMC in Amsterdam to undergo periodic QCSI studies (van Dussen et al [@CR16]). In this small cohort of patients treated with either 30 or 60 units/kg every other week (EOW), a significant increase in lumbar spine FF was shown, reflecting the clearance of Gaucher cells from the bone marrow. Of the eight patients, five patients had a baseline FF below 0.23. Interestingly, the improvement occurred as early as 9 months after the beginning of treatment with taliglucerase alfa, with further improvement up to 36 months (Tekoah et al [@CR14]). Although comparable data at 9 months of therapy have not been reported for treatment with imiglucerase or velaglucerase alfa, we hypothesized that taliglucerase had a more specific beneficial effect on bone marrow involvement, and therefore we initiated a study to assess the bone marrow response to taliglucerase alfa using the same methodology of QCSI in a larger, new cohort of adult patients with GD, both treatment-naïve to ERT and those switched from imiglucerase, who received taliglucerase alfa during the 3 years of approved early access programs (EAP) in Israel.

Methods {#Sec2}
=======

The study was initiated by investigators at Shaare Zedek Medical Center (SZMC), Jerusalem, Israel, and the AMC at the University of Amsterdam, Amsterdam, the Netherlands. Patients from the Gaucher Clinic at SZMC who were eligible for the EAP included those who had previously received imiglucerase ('switch-over') and those who had never received any ERT or who had not received ERT for ≥2 years ('naïve'). The EAP excluded children and pregnant women (those patients continued with imiglucerase).

All patients (whether treatment-naïve to ERT or switched from imiglucerase) were offered the option to undergo QCSI at AMC before treatment initiation. Those who presented with a FF below 0.3 were offered an additional two follow-up examinations at 1 and 2 years from the advent of taliglucerase alfa therapy. Travel and QCSI costs were covered by Protalix Biotherapeutics.

Most patients in this study received taliglucerase alfa 30 units/kg EOW with the exception of four patients; three 'naïve' patients received 60 units/kg EOW because of significant thrombocytopenia and bleeding tendency (*n* = 1) and the need for dose increase during the study due to poor platelet response (*n* = 2) (Table [1](#Tab1){ref-type="table"}). One 'switch-over' patient originally from the expanded access protocol PB-06-004 (NCT00962260) continued with taliglucerase alfa 15 U/kg EOW (Table [2](#Tab2){ref-type="table"}). For the majority of the patients who switched from imiglucerase the 30 U/kg, EOW was, in fact, a dose increase (doubled). None of the switched patients experienced any interruption of imiglucerase ERT prior to the advent of taliglucerase alfa treatment.Table 1Demographics and lumbar spine FF assessments in treatment-naïve patients (*n* = 15)P\#Age, yrGenderTaliglucerase alfaLumbar spine FFDuration, yrDose, U/kgBaselineYear 1Year 2Lumbar spine FF ≤0.30 4666Female2300.150.260.41 1768Female3.3300.160.250.27 2948Female5300.170.530.59 3345Female4.5300.210.360.35 41\*41Female4.5300.21---- 32\*32Female0.5300.23---- 18\*65Female1300.27---- 4447Male4.2300.270.360.41 1363Male4600.300.390.44Lumbar spine FF \>0.30 23§46Female5300.31---- 35^†^55Male4.560^‡^0.320.430.45 38^†^34Male4300.320.540.50 42^§^24Female4.5300.39---- 34^§^65Female460^‡^0.40---- 31^§^60Male4.7300.43----P, patient; yr., year; U, unit; FF, fat fraction\*Withdrew from the study (early withdrawal due to allergic reaction \[n = 1\] and personal reasons \[n = 2\]). ^†^Two patients with lumbar spine FF \>0.30 were followed via quantitative chemical shift imaging (one due to severe osteoporosis and the other due to very severe phenotype at baseline). ^‡^Taliglucerase alfa dosing was started at 30 U/kg and increased to 60 U/kg. ^§^Not followed with QCSI because baseline lumbar spine FF was \>0.30Table 2Demographics and lumbar spine FF assessments in treatment-switch patients (*n* = 11)P \#Age, yrGenderDuration of imiglucerase, yrDose of imiglucerase, U/kgDuration of taliglucerase alfa, yrDose of taliglucerase alfa, U/kgLumbar spine FFBaselineYear 1Year 2Lumbar spine FF ≤0.30 3742Female15154.5300.080.050.08 3058Female17305300.130.290.44 1435Female2.2154300.170.310.31 1933Female7.6154.5300.170.150.26 143Female17151.5150.190.29-- 2239Male14154.7300.240.340.36 3944Female14154.5300.260.300.35 3669Male6.5154.5300.280.340.34Lumbar spine FF \>0.30 25\*34Male6.5155300.46---- 27\*50Male0.9150.5300.49---- 20\*40Male8155300.51----P, patient; yr., year; U, unit; FF, fat fraction\*Not followed by quantitative chemical shift imaging because baseline lumbar spine FF was \>0.30

The QCSI was performed on a Siemens Avanto machine, as previously reported (van Dussen et al [@CR16]). Lumbar spine FF was calculated as the average of readings for L3, L4, and L5 using a standard algorithm developed by the AMC. When obtaining consecutive measurements from patients, a special effort was taken to reposition the image slide on the mid-sagittal localizer as close as possible to obtain regions of interest for L3, L4, and L5 in a standardized manner. This protocol was reproducibile (standard deviation of repeated measurements of 0.01--0.03) (Maas et al [@CR7]; Maas et al [@CR9]). The QCSI technique in the AMC institute has been part of regular clinical routine for two decades and undergoes regular quality assessment (van Dussen et al [@CR15]).

Institutional review board approval was granted for the study and all participating patients provided written informed consent before commencing study procedures.

Statistical analysis {#Sec3}
--------------------

Descriptive statistics were employed. Absolute changes in bone marrow FF were calculated. Differences in FF compared to baseline after the 1st and 2nd year in 'naïve' and in 'switch-over' patients were tested using the related samples Wilcoxon signed ranks test. Statistical analysis was performed with SPSS statistical package (version 22 for Windows). A *P* value \<0.05 was considered significant.

Results {#Sec4}
=======

Of the 22 treatment-naïve patients who were given at least one dose of taliglucerase alfa, 15 patients agreed to participate in the study and were referred for baseline QCSI at AMC (Fig. [1](#Fig1){ref-type="fig"}). Median FF at baseline was 0.27 (range 0.16--0.43) (see Table [1](#Tab1){ref-type="table"}). Eight patients performed follow-up QCSI assessments after the 1st and 2nd year of therapy. All patients showed significant improvement in FF as early as 1 year of taliglucerase alfa from a median baseline FF of 0.24 (0.15--0.32) to 1st year FF of 0.37 (0.25--0.54) and 2nd year FF of 0.42 (0.27--0.59) (*p* = 0.01) (Table [1](#Tab1){ref-type="table"}). Importantly, all four treatment-naïve patients with FF \< 0.23 changed FF category from "bone at risk" to "no risk". The QCSI results from treatment-naïve patients with a baseline lumbar spine FF ≤ 0.30 are shown in Fig. [2](#Fig2){ref-type="fig"}a.Fig. 1Patient disposition in the Early Access Program. \*Two patients with lumbar spine fat fraction (FF) \>0.30 were followed via quantitative chemical shift imaging (QCSI) (one due to severe osteoporosis and the other with very severe phenotype at baseline). ^†^Not followed with QCSI because baseline FF was \>0.30Fig. 2**a** Quantitative chemical shift imaging (QSCI) findings from treatment-naïve patients with lumbar spine fat fraction (FF) ≤0.30 at baseline.**b** Quantitative chemical shift imaging (QSCI) findings from treatment-switch patients who remained at the same dose

Of the 21 patients who received taliglucerase alfa after being treated with imiglucerase ('switch-over' patients), 11 patients agreed to participate in the study (Fig. [1](#Fig1){ref-type="fig"}b). Median FF at baseline was 0.24 (range 0.08--0.51). All eight patients with FF \< 0.3 performed at least one follow up assessment (Table [2](#Tab2){ref-type="table"}). Seven patients significantly improved over baseline from a median baseline FF of 0.17 (0.08--0.28) to 1st year FF of 0.3 (0.05--0.34) and 2nd year FF of 0.34 (0.08--0.44) (*p* = 0.035 and 0.027, respectively). One patient with FF of 0.08, the lowest in the cohort of 'switch-over' patients (after 15 years imiglucerase), did not increase the FF after the 'switch-over' despite a doubling of the dose. The improvements in QCSI parameters for the two 'switch over' patients who remained at the same dose (Table [2](#Tab2){ref-type="table"}, P\#30; P\#1) are shown in Fig. [2](#Fig2){ref-type="fig"}b.

Discussion {#Sec5}
==========

Taliglucerase alfa, the first plant-cell expressed human recombinant therapeutic protein, is the third ERT approved for the treatment of adults and children with type 1 GD (Shemesh et al [@CR12]; Stirnemann et al [@CR13]). Its safety and efficacy have been demonstrated in three double-blind two-dose (30 and 60 units/kg EOW) comparative clinical trials: treatment-naïve adults (Zimran et al [@CR20]), treatment-naïve children (Zimran et al [@CR23]), and in a switch-over trial with both adult and pediatric patients who had been previously treated with imiglucerase (Pastores et al [@CR10]). In all these trials (as in other trials of ERTs for GD), efficacy endpoints were a reduction in spleen and liver volumes and improvement in hematological parameters, whereas the impact on bones has been considered exploratory because of the slower response of the skeleton to alglucerase and to imiglucerase (Lebel et al [@CR6]).

During the clinical development program of taliglucerase alfa, it was speculated that the presence of 100% mannose residues compared to only 40--60% in imiglucerase (Tekoah et al [@CR14]) could account for the better penetrance of taliglucerase alfa into bone marrow macrophages. Therefore, the option of QCSI examination was offered as an additional skeletal (exploratory) end-point.

The current report reinforces the earlier findings of clinically meaningful early improvement in bone marrow FF of the lumbar spine in patients naïve to ERT (van Dussen et al [@CR16]). Importantly, the QSCI in 'switch-over patients was studied here for the first time, demonstrating improvement of FF among the majority of those patients. However, because many of the switched patients had their dosage increased from 15 to 30 units/kg EOW, one cannot claim a "booster effect" in bone response by virtue of the switch alone. Several reports have already demonstrated dose-response relations in the bone changes as measured by bone densitometry (Wenstrup et al [@CR18]) and by bone marrow burden score assessed by MRI (de Fost et al [@CR2]). Of interest is the improvement in QCSI parameters of the two patients who remained at the same dose. These patients, age 43 and 58 years, remained at the same dose as before the switch and, despite very low FF values after 17 years on imiglucerase, changed category from "bone at risk" (0.13; 0.19, respectively) to FF = 0.29 after 1 year of taliglucerase alfa and to FF = 0.44 for one of the patients at 2 years. As conversion to fatty marrow may occur during aging, especially in peri-menopausal patients, it is not clear if this phenomenon has influenced the outcome. The female with poor response to taliglucerage alpha (\#37) was most probably a poor responder with severe stable bone disease. Over the years there was no evidence for antibody formation, myelofibrosis, and/or other underlying bone disease that could explain her lack of response to the increased taliglucerase doses. We acknowledge that the small cohort and variable results should be interpreted with caution. However, if these observations would be seen in larger cohorts of patients, there may be a medical indication to switch patients with low FF values despite long-term exposure to other Gaucher-specific treatments to taliglucerase alfa.

The QCSI is considered the most sensitive and specific imaging modality to assess bone marrow involvement and response to Gaucher-specific therapy (van Dussen et al [@CR15]); yet its very restricted availability is the main limitation of the current and future studies.

The early improvement in QCSI results observed in the treatment-naïve patients is similar to the early improvement in bone marrow burden scores evaluated in the velaglucerase alfa clinical trial (Elstein et al [@CR3]). As both taliglucerase alfa and velaglucerase alfa share a complete mannose residues profile (100% versus 40--60% on imiglucerase), if confirmed in a larger cohort, we hypothesize that this preferred glycan structure of the enzymes may possibly be responsible for the early response of the bone marrow FF to these two newer ERTs.

The study has several limitations. In addition to the limited number of patients studied to support a booster effect of taliglucerase and the potential effect of aging on the observed improvement, we have not observed any bone events in these patients, although the general agreement is that a low FF is associated with an increased risk for complications.

In conclusion, the current report adds to the overall satisfying efficacy profile of taliglucerase alfa in adult patients with type 1 GD, and again suggests a beneficial impact on the bone marrow compartment, a parameter that has heretofore been considered slower to response compared to the hematological and visceral disease features. Further studies are needed to establish a true "booster effect" of taliglucerase on the bone marrow compartment.
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